Switzerland· 67680002
Nicardipin Aguettant 10 mg/10 ml, solution injectable
A nicardipine product containing nicardipini hydrochloridum, registered in Switzerland by Aguettant Suisse SA and dispensed under Swissmedic category A. The same ATC class is registered in 8 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Nicardipine is registered in 8 of 19 countries.
Countries holding a registration under ATC C08CA04 (nicardipine), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 5 of them publish a price we can compare per daily dose
Nicardipine · ATC C08CA04
8 / 19 countries
- Belgiumprice
- Franceprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- nicardipini hydrochloridum
- Manufacturer
- Aguettant Suisse SA
- Country
- Switzerland (CH)
- ATC code
- C08CA04
- ATC class
- Nicardipine
- Defined daily dose
- 90 mg, O
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
228 interactions on record for nicardipine.
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nicardipine · interactions on record
228 records
- 8 severe
- 173 moderate
- 1 minor
- 46 info
Most severe, free to view
- DolasetronA04AA04severe
- CeritinibL01ED02severe
- CeritinibL01XE28severe
- MitotaneL01XX23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nicardipine in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumNicardipine Aguettant 10 mg/10 mlLaboratoire Aguettant
- United StatesCardene IVBaxter Healthcare Corporation
- United KingdomCardene 20mg capsulesWaymade Healthcare Plc
- SpainFLUSEMIDE 20 mg COMPRIMIDOSLaboratorios Q Pharma S.L.
- FranceLOXEN 10 mg/10 mL, solution injectable (I.V.)LABORATOIRE XO
- ItalyNICARDIPINA*30 cps 40 mg rilascio prolungatoMYLAN SpA
- NetherlandsCardene IV, 1 mg/ml oplossing voor infusieLaboratoire X.O.
- NorwayNicardipine HCl hikmaHikma
Authorised across Europe · EMA
The same active substance is authorised in 7 EEA countries. Names it is sold under:
- Belgium · Nicardipine Aguettant, Nicardipine Hikma
- Spain · Flusemide, Nerdipina Retard
- France · Loxen, Loxen Lp
- United Kingdom (Northern Ireland) · Nicardipine Hydrochloride Tillomed Laboratories, Nicardipine Laboratoire Aguettant
- Italy · Nicardipina Mylan Generics
- Luxembourg · Nicardipine Aguettant, Rydene Iv
- Netherlands · Cardene Iv
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f507f18e-8024-4e9a-881f-b265d9dc8529 GET /v1/drugs/f507f18e-8024-4e9a-881f-b265d9dc8529?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about nicardipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.